Next Gen Lipid-Based Nanoparticles Delivery Summit

Memo

The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery. The industry is now poised to exploit the full therapeutic potential of these vehicles for emerging payloads and extrahepatic delivery. The Next Generation Lipid-Based Nanoparticles Delivery Summit is your definitive industry-led meeting to design and engineer 2nd generation of lipid nanoparticles for emerging payloads beyond RNA into clinic. Join Intellia Therapeutics, Entos Pharmaceuticals, AstraZeneca, Eli Lilly, and other scientific trailblazers as they navigate the next generation of lipid-based nanoparticles for targeted delivery to expedite innovative treatments for unmet patient needs. Over 3 days, we will: Explore translating novel lipid chemistry and design – reviewing the journey from liposomes to LNP, from synthetic LNPs to lipid nano-crystals – to maximize cytosolic delivery and minimize immunogenicity and toxicity Unlock the full potential of nanoparticles and assess lipid-based for new payloads – including CRISPR Cas9, DNA, cell & gene therapies, oligos and macromolecules Improve the safety and efficacy of lipid-based delivery beyond RNA through formulation, particle engineering, and chemical design to overcome intracellular barriers Tickets https://go.evvnt.com/1071429-1?pid=5569Brochure https://go.evvnt.com/1071429-2?pid=5569 Prices:Drug Developer Pricing - Conference + 3 Workshops USD 4946.00Drug Developer Pricing - Conference + 2 Workshops USD 4297.00Drug Developer Pricing - Conference + 1 Workshop USD 3648.00Drug Developer Pricing - Conference Only USD 2999.00Solution Provider Pricing - Conference + 3 Workshops USD 5846.00Solution Provider Pricing - Conference + 2 Workshops USD 5097.00Solution Provider Pricing - Conference + 1 Workshop USD 4348.00Solution Provider Pricing - Conference Only USD 3599.00 Speakers: Bryant Nelson, Staff Research Chemist, National Institute of Standards & Technology, Priya Karmali, Chief Technology Officer, Capstan Therapeutics, John Lewis, Founder & Chief Executive Officer, Entos Pharmaceuticals, Chun-Wan Yen, Principal Scientist, Genentech, Cory Sago, Senior Director & Head of LNP Discovery, Beam Therapeutics, Dominik Witzigmann, Co-Founder & Chief Executive Officer, Nanovation Therapeutics, Hemant Kumar, Chief Technology & Manufacturing Officer, Genprex, Hila Epstein-Barash, Chief Research & Development Officer, Azura Ophthalmics, James Ferguson, Chief Medical Officer, Matinas BioPhma, Kalina Paunovska, Postdoctoral Scholar Dahlman Lab, Georgia Institute of Technology, Ruchi Shah, Associate Director, New Therapeutic Modalities, Eli Lily, Kristina Friis, Senior Scientist, Advanced Drug Delivery, AstraZeneca, Sonya Zabludoff, Vice President, Clinical Development, Nitto BioPharma, Manuel Sanchez-Felix, Senior Fellow, Novel Delivery Technologies, Novartis, Qiaobing Xu, Founder & Chief Executive Officer, Hopewell Therapeutics, Bharat Majeti, Director, Drug Delivery Platform Development, Nitto BioPharma, Rajesh Shinde, Senior Director of Manufacturing & Technology Operations, Genprex, Xiuling Lu, Associate Professor, University of Connecticut, Zhili Li, Senior Director of Research, Insmed Dates and Time: Starts: Tue, Jul 19, 2022 ( 9:00 AM) and Ends: Thu, Jul 21, 2022 ( 3:30 PM) Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States